State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019: allogeneic stem cell transplantation for myelofibrosis in 2019
Standard
State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019: allogeneic stem cell transplantation for myelofibrosis in 2019. / McLornan, Donal P; Yakoub-Agha, Ibrahim; Robin, Marie; Chalandon, Yves; Harrison, Claire N; Kroger, Nicolaus.
in: HAEMATOLOGICA, Jahrgang 104, Nr. 4, 04.2019, S. 659-668.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019: allogeneic stem cell transplantation for myelofibrosis in 2019
AU - McLornan, Donal P
AU - Yakoub-Agha, Ibrahim
AU - Robin, Marie
AU - Chalandon, Yves
AU - Harrison, Claire N
AU - Kroger, Nicolaus
N1 - Copyright© 2019 Ferrata Storti Foundation.
PY - 2019/4
Y1 - 2019/4
N2 - Advances in understanding the pathogenesis and molecular landscape of myelofibrosis have occurred over the last decade. Treating physicians now have access to an ever-evolving armamentarium of novel agents to treat patients, although allogeneic hematopoietic stem cell transplantation remains the only curative approach. Improvements in donor selection, conditioning regimens, disease monitoring and supportive care have led to augmented survival after transplantation. Nowadays, there are comprehensive guidelines concerning allogeneic hematopoietic stem cell transplantation for patients with myelofibrosis. However, it commonly remains difficult for both physicians and patients alike to weigh up the risk-benefit ratio of transplantation given the inherent heterogeneity regarding both clinical course and therapeutic response. In this timely review, we provide an up-to-date synopsis of current transplantation recommendations, discuss usage of JAK inhibitors before and after transplantation, examine donor selection and compare conditioning platforms. Moreover, we discuss emerging data concerning the impact of the myelofibrosis mutational landscape on transplantation outcome, peritransplant management of splenomegaly, poor graft function and prevention/management of relapse.
AB - Advances in understanding the pathogenesis and molecular landscape of myelofibrosis have occurred over the last decade. Treating physicians now have access to an ever-evolving armamentarium of novel agents to treat patients, although allogeneic hematopoietic stem cell transplantation remains the only curative approach. Improvements in donor selection, conditioning regimens, disease monitoring and supportive care have led to augmented survival after transplantation. Nowadays, there are comprehensive guidelines concerning allogeneic hematopoietic stem cell transplantation for patients with myelofibrosis. However, it commonly remains difficult for both physicians and patients alike to weigh up the risk-benefit ratio of transplantation given the inherent heterogeneity regarding both clinical course and therapeutic response. In this timely review, we provide an up-to-date synopsis of current transplantation recommendations, discuss usage of JAK inhibitors before and after transplantation, examine donor selection and compare conditioning platforms. Moreover, we discuss emerging data concerning the impact of the myelofibrosis mutational landscape on transplantation outcome, peritransplant management of splenomegaly, poor graft function and prevention/management of relapse.
KW - Disease-Free Survival
KW - Hematopoietic Stem Cell Transplantation
KW - Humans
KW - Primary Myelofibrosis/blood
KW - Recurrence
KW - Survival Rate
KW - Transplantation Conditioning
KW - Transplantation, Homologous
U2 - 10.3324/haematol.2018.206151
DO - 10.3324/haematol.2018.206151
M3 - SCORING: Review article
C2 - 30872371
VL - 104
SP - 659
EP - 668
JO - HAEMATOLOGICA
JF - HAEMATOLOGICA
SN - 0390-6078
IS - 4
ER -
